WO1997046244A1 - Compositions and method which retard the aging process and which improve age-related disease conditions - Google Patents

Compositions and method which retard the aging process and which improve age-related disease conditions Download PDF

Info

Publication number
WO1997046244A1
WO1997046244A1 PCT/US1996/009440 US9609440W WO9746244A1 WO 1997046244 A1 WO1997046244 A1 WO 1997046244A1 US 9609440 W US9609440 W US 9609440W WO 9746244 A1 WO9746244 A1 WO 9746244A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic field
effective amount
serotonin
pulsed magnetic
composition
Prior art date
Application number
PCT/US1996/009440
Other languages
French (fr)
Inventor
Reuven Sandyk
Original Assignee
Reuven Sandyk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reuven Sandyk filed Critical Reuven Sandyk
Priority to CA002257279A priority Critical patent/CA2257279A1/en
Priority to IL12740096A priority patent/IL127400A0/en
Priority to PCT/US1996/009440 priority patent/WO1997046244A1/en
Priority to AU59898/96A priority patent/AU5989896A/en
Publication of WO1997046244A1 publication Critical patent/WO1997046244A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Definitions

  • the pineal gland is recognized as a neuroendoc ⁇ ne transducer, whose chief function is that of synchronizing endogenous circadian rhythms via the conversion of neuronal impulses to melatonin release. Aging is characterized by disorganization of circadian rhythms caused in part by the progressive decline m the activity of the pineal gland leading ultimately to pineal failure
  • the pineal gland is a agnetosensor organ and its functions can be enhanced by the external application of pulsed magnetic fields
  • These disorders which are associated with and/or related pathogenetically to impairment of pineal melatonin functions included multiple sclerosis, Parkinson's disease, dystonia, tardive dyskmesia, epilepsy, migraine, Alzheimer's disease, depression (including seasonal affective disorder and late luteal phase dyspho ⁇ c disorder) , schizophrenia, Gilles de la Tourette ' s syndrome, Attention deficit hyperactivity syndrome, anxiety and panic disorder, obsessive compulsive disorder, narcoiepsy-cataplexy, myoclonus, akathisia and restless legs syndrome and chronic pain syndromes.
  • neuroendocrme transducer an organ which converts neural signals from the external environment such as photic, acoustic, thermic, and magnetic cues into neuroendocrme output which acts on the nervous system largely via the secretion of its principal hormone melatonin.
  • the pineal gland is unique among endocrine organs for a number of reasons: (1) it is one of the few unpaired endocrine organs, (2) on a weight basis, it receives one of the richest blood supplies of any organ; (3) it lies outside the blood brain barrier, but has direct access to the cerebrospmal fluid (CSF) via the third ventricle; (4) it produces and/or contains high concentrations of a number of different mdoleamines and low molecular weight peptides of probable endocrine importance, ana (5) it is responsive to changes in magnetic field strength and to external electrical stimuli (Foley et al.
  • pinealecto y results in a syndrome of deficits which include disruption of circadian rhythms and sleep phases, facilitation of a narcoleptic-type REM sleep distribution, increased susceptibility to epileptic seizures, facilitation of abnormal orofacial involuntary movements, decreased tolerance to heat, impairment of opioid analgesia, reduction in brain neurotransmitter levels such as serotonin and GABA, delayed brain maturation, impaired electrolyte balance specifically sodium, calcium and phosphorus metabolism, arterial nypertension, increased plasma cortisol levels, disruption of adrenomedullary diurnal catecholamine synthesis, a biochemical diabetes-like state, elevation of blood cholesterol levels, disruption of circadian rhythms of gonadotropms and testosterone with resultant enlargement of the prostate, impaired wound healing, and promotion of cancer growth due to disruption of immunomodulation and reduced ability to protect cell membranes from peroxidative damage (Armstrong and Redman (1991) "Melatonin
  • melatonin deficiency includes, among others, decrease in cerebral energy metabolism with decline m memory and other cognitive functions, tendency to depressive mood, decline in the percentage of alpha brain waves, deterioration of sleep efficiency with increased number of nocturnal awakenings, increased daytime sleepiness, diminished immune functions with increased probability of cancer and autoimmune diseases, deterioration of metabolic and endocrine homeostasis, impaired gastrointestinal motility, susceptibility to the development of psoriasis, acceleration of atherosclerosis, poor wound healing, and decreased longevity (Reiter, R.J.
  • Melatonin has been considered a chronobiotic hormone, i.e., a hormone that can act as a synchronizer or "Zeitgeber” to reset the phase of biological rhythms by acting on the circadian pacemaker in the suprachiasmatic nucleus of the hypothalamus (Armstrong and Redman (1991) "Melatonin: a chronobiotic with antiagmg properties?" Medical Hypotheses, 34, 300-309) .
  • pineal melatonin functions may result in the disruption of biological rhythms of numerous biochemical, physiological, hormonal, and behavioral systems leading to disease and ag g (Armstrong and Redman (1991) "Melatonin: a chronobiotic with anti-aging properties 7 " Medical Hypotheses, 34, 300-309; Ingram et al . , (1982) "Circadian rnythmicity and sleep:effects of agmg in laboratory animals " Neurobiology of Agmg, 3, 287-297, Van Gool et al . (1987) "Age-related changes in circadian sleep-wakefullness rhythms m male rats isolated from time cues.” Brain Research, 413, 384-387)
  • melatonin is a chronobiotic hormone it may be used therapeutically to re-entra short-term dissociated or long- term desynchronized circadian rhythms or physiologically prevent their disruption following environmental msult and thus correct many of the pathological conditions which are associated with p eal failure associated with agmg
  • melatonin administered to humans alleviates the deleterious effects of jet-lag, prolongs deep stages of sleep (i.e., restores youthful sleep patterns) and improves mood (Arendt et al.
  • melatonin acts as an anti-aging hormone
  • Growth hormone is an anabolic hormone which stimulates protein synthesis, bone growth and glucose metabolism. In addition, it promotes inhibition of fat formation and causes improved sleep energy, enhancement of immune functions, and stimulation of nerve growth factors (Quabbe (1985) "Hypothalamic control of GH secretion:pathophysiology and clinical implications.” Acta Neurochirurgica, 75, 60-71; Astrom and Trojaborg (1992) "Effect of growth hormone on human sleep energy.
  • my present invention additionally includes administering an effective amount of an agent which promotes growth hormone release prior to application of the AC pulsed magnetic field.
  • the amino acids L-arginine and L-ornithine both stimulate the release of growth hormone in humans (Martin and Reichlin (1987) "Regulation of growth hormone secretion and its disorders" In Clinical neuroendocrinology (p. 237) F.A. Davis: Philadelphia) .
  • the activity of the pineal gland and hence the rate of melatonin secretion is influenced also by the earth's geomagnetic field which is in the order of 30,000 - 60,000 nanotesla (0.3 - 0.6 Gauss)
  • the earth's magnetic field is primarily a nontime-varymg (DC) field with angle of incidence to the earth's surface increasing with increasing latitude.
  • anthropogenic magnetic fields are primarily time varying at 50 or 60 Hz and harmonic of these frequencies. Typical magnetic fields measured m residential settings range from 0.1 microtesla to 3 microtesla at 60 Hz frequency.
  • the geomagnetic field has been a part of the environment throughout the evolution of animals and is used by certain species m their adaptive strategies Organisms are capable of perceiving its intensity, polarity, and direction (Gould (1984) "Magnetic field sensitivity animals.” Annual Review of Physiology, 46, 585-598) . It is thought that the circadian rhythmicity of the earth's magnetic field may have an additional "Zeitgeber" (time cue) function m the organization of biological rhythms (Cremer-Bartels et al.
  • circadian rhythmicity of the earth's magnetic field may have an additional "Zeitgeber" function in the organization of biological rhythms (Cremer- Bartels et al . (1984) "Magnetic field of the earth as additional zeitgeber for endogenous rhythms?" Naturwissenschaften, 71, 567-574) .
  • melatonin is a "master hormone" involved in the programming of the aging process and as aging is associated with pineal failure and administration of melatonin or pineal extracts prolongs life span in experimental animals, I believe that activation of the pineal gland by periodic application of pulsed magnetic fields may be used to retard the aging process and therapeutically to improve pathological states which are linked to or result from pineal failure due to aging such as sleep disturbances, loss of memory functions, disturbances of behavior, and depressive mood.
  • pulsed magnetic fields have been shown in normal elderly subjects to alleviate the deleterious effects of jet-lag (1 e , fatigue, malaise) , improve sleep efficiency, restore dream recall, increase level of energy and improve mood, promote relaxation, improve level of concentration, enhance sexual functions, improve bowel functions with resolution of constipation, normalize previously mcrease ⁇ plasma levels of cholesterol, normalize previously elevated blood glucose levels, normalize previously elevated blood pressure, dimmish the activity of psoriatic skin lesions, and enhance immune functions (i.e , prevent exacerbation of herpes infection; dimmish frequency of influenza infections) .
  • the most dramatic effects of pulsed magnetic fields m normal adult and elderly subjects mcluded improvement in sleep, mood, behavior (agitation and impulsive aggressive behavior) , and short-term memory functions.
  • Parkinson's disease anatomy, pathology and therapie .
  • New York: Raven Press; Langston (1988) Agmg, neurotoxins, and neurodegenerative disease.
  • Agmg and the brain (pp.
  • the calcified material which consists of hydroxyapatite and calcium carbonate apatite crystals as well as high concentrations of several trace elements such as iron, magnesium, zmc, copper, and manganese (Humbert and Pevet (1991) "Calcium content and concretions of pmeal glands of young and old rats " Cell and Tissue Research, 263, 593-596) may altei the physicochemical properties of the gland and interfere with the ability of the pmeal glan ⁇ to release melatonin m response to magnetic fields,- (b) Reduction the activity of the p eal gland in agmg may be related to various factors including, among others, increased accumulation of agmg pigment in the p ealocytes, decrease m pmeal receptor sensitivity and/or density, decline in the availability of nutritional co-factors for serotonin and melatonin synthesis, decline in the capacity of pineal cells to synthesize serotonin from tryptophan, and decrease sympathetic nervous
  • Agmg is associated with diminished serotonin receptor density and cerebral concentrations of serotonin, a precursor of melatonin synthesis. In addition, levels of the ammo-acid tryptophan, a precursor of serotonin synthesis, are reduced the blood of a proportion of elderly people who fail to absorb tryptophan (Ingram et al . (1982) "Circadian rhythmicity and sleep: effects of ag g in laboratory animals.” Neurobiology of Agmg.
  • the present invention relates to the use of a pulsed magnetic field in combination with a pharmacological-nutritional composition to retard the agmg process and improve age-related disease conditions. More particularly, the present invention relates to the enhancement of the activity of the pmeal gland and specifically the production of its principal hormone melatonin which is considered a "master hormone" m the regulation of biological rhythms.
  • the purpose of the composition is to sensitize the p eal gland to the effects of magnetic fields.
  • My mvention includes a method of retarding the agmg process and improving the symptoms of age-related disease conditions in humans which comprises administering to a human m need thereof an effective amount of a composition which increases serotonin transmission to such human followed py the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform.
  • This composition is preferably supplemented by a dietary composition rich in the ammo-acid tryptophan.
  • my invention includes administering an effective amount of an agent which promotes growth hormone release prior to the application of the AC pulsed magnetic field.
  • My invention also includes the above referred to composition for increasing serotonin transmission to humans, which composition may optionally include an effective amount of an agent which promotes growth hormone release.
  • My composition comprises an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the brain, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors, and is preferably supplemented by an effective amount of a dietary composition rich m the ammo-acid tryptophan.
  • Plasma melatonin concentrations decline progressively with age with a steeper decline occurring m men at about the age of 50 years while in women a more dramatic decline occurs perimenopausally starting at the age of 45 years (Nair et al . (1986) "Plasma melatonin- an index of brain agmg humans?" Biological Psychiatry, 21, 141-150; Sack et al. (1986) "Human melatonin production decreases with age " Journal of Pmeal Research, 3, 379-388) .
  • the procedure to retard the agmg process m men should begin at about the age of 50 while in women the procedure should begin earlier around the age of 45 years coincident with the fall of p eal melatonin production perimenopausally
  • the AC pulsed magnetic field is applied to the bram of the human in two applications separated by an interval of time.
  • the duration of the first AC pulsed magnetic field is 10 to 15 minutes
  • the duration of the second AC pulse is also preferably 10 to 15 minutes. It is preferred that the time delay between the application of the first AC pulse and the application of the second AC pulse is 15 to 30 minutes.
  • the composition comprises one or more of the following: an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the bram, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors.
  • the effective amount of a dietary composition rich m the ammo-acid tryptophan s a preferred supplement to my composition and comprises including in the diet of the person to be treated various foods wnich are rich tryptophan.
  • My composition may optionally include an effective amount of an agent which promotes growth hormone release
  • the serotonin precursor is L-tryptophan (L-TP) or L-5 hydroxytryptophan (L-5-HTP) Since serotonin present in tne blood is excluded by the blood bra barrier from entry mto the bram, the administration of precursors such as L-TP or L-5-HTP is used to increase brain concentrations of serotonin (Wurtman and Fernstrom (1975) "Control of bram monoam e synthesis by diet and plasma ammo-acids.” The American Journal of Clinical Nutrition, 28, 638-647)
  • the stimulant to facilitate the transport of a serotonin precursor mto the bra is one which facilitates the transport of tryptophan mto the brain. It is preferably vitamin B 3 , chromium (preferably chromium picolmate) or a mixture thereof Chromium is an essential co-factor to insulin production and action (Rabinowitz et al.
  • the agent to increase plasma tryptophan concentrations is a salicylate.
  • L-tryptophan is usually transported m the blood in a bound or complexed form with the protein albumin. It nas been shown that various salicylates displace tryptophan from its protein binding site with albumin in blood plasma thereby raising the free or unbound tryptophan concentration m the blood
  • the bond-breaking effect exerted by salicylates cn the binding of tryptophan to albumin causes a greater availaoility of free tryptophan for diffusion into the bram (Tagliamonte et al .
  • the stimulant of serotonin synthesis is preferably vitamin B, , vitamin B2, vitamin B 3 , vitamin B 6 , biotm, S- adenosyl ethionine, folic acid, ascorbic acid, magnesium, coenzy e Q 10 , piracetam or mixtures of two or more thereof.
  • the stimulant of serotonin release is preferably fenflura me (Fuller (1986) "Pharmacologic modification of serotonergic functions- drugs for the study and treatment of psychiatric and other disorders " Journal of Clinical Psychiatry, 47 (suppl 4) , 4-8) .
  • the stimulant of serotonin receptors is preferably ergoloid mesylates (Hydergine ® ) .
  • Hyderg e ® has been shown to improve mental alertness and memory functions m normal subjects and those with organic mental deterioration an effect which is related partly to its stimulating properties of serotonin receptors m the brainstem reticular formation (Depoortere et al . (1975) "Neuropharmacological studies on Hydergine.” Triangle, 14, 73-79) .
  • the dietary composition should include foods which are rich the ammo-acid tryptophan such as turkey (4 ounces twice a week) , milk (8 ounces per day of whole, low-fat, or skim) , bananas (1 per day) , nuts (1-2 ounces per day) and dry-roasted sunflower seeds (3-4 ounces per day) .
  • ammo-acid tryptophan such as turkey (4 ounces twice a week) , milk (8 ounces per day of whole, low-fat, or skim) , bananas (1 per day) , nuts (1-2 ounces per day) and dry-roasted sunflower seeds (3-4 ounces per day) .
  • L-argmme or L-ornithme as agents to promote growth hormone release.
  • these agents would be administered the night before and most preferably one to two hour prior to the application of the AC pulsed magnetic field.
  • the intensity of the magnetic field be the range of 7.5 - 75 picotesla.
  • the magnetic field is a time varying field with a wave form which is sinusoidal, triangular, trapezoidal, square or a composite thereof
  • the rields are preferably applied to the subject's head using a helmet-like transducer array
  • the helmet-like transducer array preferably comprises an array of coils which are flat or helical
  • the AC magnetic field frequency is 5Hz-8Hz
  • the AC pulsed magnetic field is applied to the human head once per week
  • the AC pulsed magnetic field is applied to the human head once or twice per week
  • the AC pulsed magnetic field is applied once or twice per week to the human head.
  • the AC pulsed magnetic field is applied to the human head once or twice per week
  • the AC pulsed magnetic field is applied to the human head once or twice per week.
  • the AC pulsed magnetic field is applie ⁇ to the human head once or twice per week
  • the AC pulsed magnetic field is applied to the human head once or twice per week.
  • the AC pulsed magnetic field is applied to the human head once or twice per week.
  • the AC pulsed magnetic field is applied once or twice per week
  • the AC pulsed magnetic field is applied once or twice per week.
  • the AC pulsed magnetic field is applied once or twice per week .
  • an effective amount of an agent which promotes growth hormone release is administered, it is administered prior to application of the AC pulsed magnetic field.
  • Preferred agents are L-arginine or L-ornithine.
  • the agent is preferably administered the night before preferably one to two hours prior to the application of the AC pulsed magnetic field.
  • composition be administered four to eight weeks before the application of the first AC pulsed magnetic field.
  • the AC pulsed magnetic field is a time-varying field with a waveform which is sinusoidal, triangular, trapezoidal, square or a composite thereof. It is also preferable that the subject's eyes are shielded during the application of each AC pulsed magnetic field.
  • the fields may be applied to the subject's head using a helmet-like transducer array as illustrated in the drawings.
  • the helmet-like transducer array preferably comprises an array of coils which are flat, i.e. two dimensional or helical, i.e. three dimensional.
  • My composition which is useful for retarding the aging process and improving age-related disease conditions in humans when administered to a human followed by the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform comprises an effective amount of a composition which increases serotonin transmission to the human and may optionally include an effective amount of an agent which promotes growth hormone release .
  • my composition comprises one or more of the following: an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the bram, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors.
  • the serotonin precursor is L-tryptophan or L-
  • the stimulant to facilitate the transport of a serotonin precursor into the bram is vitamin B 1( chromium or a mixture thereof .
  • the agent to increase plasma tryptophan concentration is a salicylate.
  • the stimulant of serotonin synthesis is vitamin B
  • the stimulant of serotonin release is fenfluramme.
  • the stimulant of serotonin receptors is an ergoloid mesylate.
  • the treatment procedure which I have found to be most effective is when the patient is given my composition supplemented by the dietary composition, beginning 4-8 weeks,pre erably 6-8 weeks, prior to the application of the first AC pulsed magnetic field which pulsed magnetic field is preferably applied m two treatments.
  • the patient is given the composition which comprises the stimulants to facilitate the transport of the serotonin precursor mto the bram, an agent which increases plasma tryptophan concentrations, the composition comprising the stimulants of serotonin synthesis, the stimulant of serotonin receptors, and the dietary composition rich in the ammo-acid tryptophan
  • the subject is given a serotonin precursor to augment the synthesis of serotonin and melatonin and an agent to promote the release of growth hormone.
  • L- tryptophan is the preferred serotonin precursor due to its low side effect profile and low risk of toxicity (Young (1986) "The clinical psychopharmacology of tryptophan " In Wurtman, R.J. and Wurtman, J.J. (Eds.) , Nutrition and the bra (pp. 49-88) , vol 7. New York: Raven Press) .
  • L-argmme or L-ornithme 500 mg-1,000 mg
  • the patient is given a stimulant of serotonin release
  • the inventor uses the drug fenfluramme hydrochloride (Pondim ® ; 10-20 mg, orally) .
  • the subject is given again an agent to promote the release of growth hormone such as L-argmme or L-ornithme (500 mg- 1,000 mg) .
  • the first magnetic pulse is given for a period of 10-15 minutes using an AC frequency of 5Hz-7Hz preferably an AC frequency of 5Hz .
  • a second magnetic pulse is applied for a period of 10-15 minutes using a higher AC frequency of 7Hz-8Hz.
  • the application of the second AC pulse is extremely beneficial for the treatment of neurological and mental disorders and it is therefore preferred to use a second pulse also in the case where the treatment procedure is applied for retardation of the ag g process and for the treatment of age-related disease conditions.
  • the AC pulsed magnetic fields are preferably applied via an external magnetic coil assembly, or transducer.
  • the transducer is constructed of flexible substrate which allows the transducer to be bent and positioned on the head of a patient in the form of a helmet .
  • the transducer is constructed of a set of coils positioned side-py-side m a two-dimensional array In the preferred embodiment of the invention as shown m Figs 1-4, the transducer is constructed of 16 coils arranged a matrix of four rows by four columns, and the area of each coil is preferably 3.14 cm 2 . When these coils are carrying an electric current, they produce magnetic fields with lines of force parallel to the axes of the respective coils The locations of the coils are such that the resultant magnetic fields are uniform.
  • the produced magnetic fields are alternating and their intensity can be less than approximately 60 microtesla
  • magnetic flelds strength m the range of 7 5 to 75 picotesla with an AC frequency in the range of 5Hz-8Hz
  • amplitudes above 75 picotesla w ll did not provide an additional benefit for patients with neurological and mental disorders and it is believed that amplitudes above 75 picotesla w ll not provide an additional benefit also for subjects undergoing this treatment procedure for retardation of the agmg process and for the treatment of age-related disease conditions.
  • maintenance therapy is implemented during which time the procedure is repeated once to twice per week.
  • the subject continues to take the pharmacological-nutritional composition except for the compositions which are administered the night before (i.e., L-tryptophan and L-argmme) and ust prior to the application of magnetic fields (i.e., fenfluramme and L-argmme)
  • the subject should spend at least one hour daily outdoors to maximize sunlight exposure to enhance serotonin functions and synchronize melatonin circadian rhythms (Wurtman and Wurtman (1989) "Carbohydrates and depression.” Scientific American, January, 68-75) .
  • the subject may continue to receive medications for his/her particular disease.
  • the sub j ect may continue to use his cholesterol lowering drugs while receiving the composition and the magnetic field therapy
  • this treatment procedure produced normalization of blood pressure antihypertensive drugs may be reduced or discontinued based on prior consultation with a physician With reference to Figs.
  • transducer 30 which s employed m the practice of the invention to apply magnetic fields upon the bra of a patient
  • the trans ⁇ ucer 30 comprises a set of coils 32, and is placed on the head of a patient 34 Upon energization of the coils 32 with electric current, the coils 32 produce magnetic fields which are directed into the bra , and particularly mto the area of the pmeal gland, of the patient 34
  • the patient 34 holds a cup 36 to demonstrate the inventive feature of ingesting various pharmacological and nutritional components of the composition prior to application of the magnetic fields
  • Electric current is applied to the coils 32 by a driver 38, the driver 38 including a voltage generator 40 and an output resistor 42 by which the generator 40 is coupled to the coils 32
  • a timer 44 for activating the generator 40 to provide a sequence of pulses of output voltage which are applied to the resistor 42
  • the resistor 42 has a resistance of approximately 0 5 megohm in the preferred embodiment of the invention, and the coil
  • the coils 32 and the resistor 42 constitute a series circuit between the terminals 52 and 54 of the generator 40
  • the voltage generator 40 m combination with the resistor 42 acts as a current source to provide a current to the transducer 30 proportional to the voltage outputted by the generator 40
  • the meter 50 also provides an indication of the magnitude of the current flow in the coils 32 of the transducer 30.
  • the intensity of the magnetic fields produced by the current in the coils 32 is proportional to the magnitude of the current and, accordingly, the reading cf the meter 50 serves also as an indication of the intensity of the magnetic fields applied by the transducer 30 to the patient 34.
  • the generator 40 is of well-known construction and provides a voltage with a periodic waveform.
  • the generator 40 includes controls for selecting the AC frequency of the voltage, the waveform of the voltage, and the amplitude of the voltage.
  • the voltage may be a steady DC voltage, or may be varied in frequency over a range of 0.1 Hz to 10,000 Hz.
  • the waveform may be sinusoidal, triangular, trapezoidal, square or a combination of more than one of these waveforms such as the sum of square plus sinusoid as shown in Fig. 5, by way of example.
  • the transducer 30 comprises a substrate 56 which supports the coils 32 in their respective positions in a two-dimensional array 58.
  • the array 58 has a total of 16 of the coils 32 arranged in four rows, each of the rows having four of the coils 32, as shown in Fig. 5.
  • Each coil 32 has, typically four or five turns, and has a diameter of approximately two centimeters, with an area of approximately three square centimeters.
  • there is array 58A of the coils 32A having a total of 24 coils arranged in four rows each having six coils 32A, as shown in Fig. 5A.
  • a cover layer 60 is disposed on top of the substrate 56 and the coils 32.
  • the substrate 56 and the cover layer 60 are formed of a flexible electrically-insulating plastic material which permits flexing of the transducer 30 to conform to the curvature of the subject's head.
  • the coils 32 are formed of a flexible electrically-conductive material such as copper which permits the foregoing flexing of the transducer 30.
  • the generator 40 is operated to output a peak voltage, typically, of four volts relative to ground. This voltage provides a peak current of eight microamperes which is more than enough current to provide a peak magnetic field intensity of 60 picotesla. The output voltage of the generator 40 is adjusted to provide a desired intensity to the resultant alternating magnetic fields.
  • the resistance of the resistor 42 may be reduced to provide still larger values of current for greater intensity of magnetic fields
  • the resultant magnetic fields have lines of force parallel to the axes 62 of the respective coils 32
  • the locations of the coils 32 provide that the resultant magnetic fields are uniform
  • the driver 38 and the transducer 30 or 30A are capable of providing alternating magnetic fields a frequency range of 0.1 Hz to 10 KHz, and intensity up to 60 microtesla.
  • the intensity of the alternating magnetic fields is in the range of 7.5 to 75 picotesla, and the frequency is in the range of 5Hz-8Hz
  • Fig 5 shows a sequence of two pulses of magnetic fields wherein the direction and amplitude of the magnetic fields alternate m sinusoidal fashion
  • the sinusoidal form of the alternating magnetic fields is employed in the preferred embodiment of the invention.
  • some other waveform such as the aforementioned triangular or trapezoidal or square waveform may be used if desired
  • the rise and the fall times of the waveform together may occupy from 20% to 40% of each period of the waveform.
  • the AC frequency s held constant the preferred embodiment of the invention.
  • the AC frequency may be altered, as by a frequency ramp wherein the frequency increases during the pulse, such that the end frequency is greater than the initial frequency by 10% - 30%.
  • Fig. 5 also shows the duration, A, of the first AC pulse, and the duration, B, of a rest mterval or break between the AC pulses, and the duration, C, of the second AC pulse.
  • the transmission of signals m the nervous system is such that withm the neuron (nerve cell) transmission is accomplished by propagation of an electrical signal while between neurons signal propagation is accomplished via the mediation of a neurotransmitter
  • a neurotransmitter is a molecule, such as a molecule of serotonin, dopamme, acetylcholine, and histamme, or other neurotransmitter by way of example Durmg the propagation of an electrical signal the neurotransmitter is released from the transmitter neuron ("presynaptic neuron") mto the synaptic cleft from which it diffuses across the synaptic cleft to reach specific receptors in the receiving neuron ( "postsynaptic neuron”) .
  • the transmitter neuron and the receiving receptor at the postsynaptic neuron are specific to only one type of neurotransmitter so that a plurality of differ- ent forms of the neuron transmitter/receptor allow for transmis ⁇ sion of different forms of signals by respective ones of the neurotransmitter.
  • Neurotransmitters are produced m numerous locations throughout the nervous system. For instance, serotonin is produced in neurons that originate the median raphe of the bramstem and which project to numerous bram areas including the spinal cord, cerebellum, hypothalamus, limbic system, and cortex. In the central nervous system serotonin affects mood, sleep and arousal, satiety, emesis, cardiovascular regulation, temperature control, pain, sedation, anxiety and depression. In the peripheral nervous system, the primary actions of serotonin are on the gastrointestinal tract and cardiovascular system, but it also affects the respiratory tract and genito-urmary system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of retarding the aging process and improving the symptoms of age-related disease conditions in humans which result from diminished pineal melatonin functions and reduced serotonin neurotransmission is described which comprises administering to a human in need thereof an effective amount of a composition which increases serotonin transmission to said human followed by the application to the brain of the human an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform. Preferably the composition is supplemented by an effective amount of dietary composition rich in the amino-acid tryptophan. Optionally an effective amount of an agent which provides growth hormone release is also administered prior to the application of the AC pulsed magnetic field. A composition useful for retarding the aging process and improving the symptoms of aging in humans which result from diminished pineal melatonin functions and reduced serotonin neurotransmission when administered to a human followed by the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform, is described which composition comprises an effective amount of a composition which increases serotonin transmission to said human. Optionally, the composition can also include an effective amount of an agent which promotes growth hormone release.

Description

COMPOSITIONS AND METHODS WHICH
RETARD THE AGING PROCESS AND WHICH
IMPROVE AGE-RELATED DISEASE CONDITIONS
BACKGROUND OF THE INVENTION The pineal gland is recognized as a neuroendocπne transducer, whose chief function is that of synchronizing endogenous circadian rhythms via the conversion of neuronal impulses to melatonin release. Aging is characterized by disorganization of circadian rhythms caused in part by the progressive decline m the activity of the pineal gland leading ultimately to pineal failure The pineal gland is a agnetosensor organ and its functions can be enhanced by the external application of pulsed magnetic fields
In my US Patent No. 5,470,846 issued November 28, 1995, and my concurrently filed con inuation-ln-part thereof Serial No. 08/437273 filed May 8, 1995 (CIP-1) , I described compositions and methods for treating neurological and mental disorders which are associated with and/or related pathogenetically to deficient serotonin neurotransmission and impaired pineal melatonin functions m humans.
These disorders which are associated with and/or related pathogenetically to impairment of pineal melatonin functions included multiple sclerosis, Parkinson's disease, dystonia, tardive dyskmesia, epilepsy, migraine, Alzheimer's disease, depression (including seasonal affective disorder and late luteal phase dysphoπc disorder) , schizophrenia, Gilles de la Tourette ' s syndrome, Attention deficit hyperactivity syndrome, anxiety and panic disorder, obsessive compulsive disorder, narcoiepsy-cataplexy, myoclonus, akathisia and restless legs syndrome and chronic pain syndromes.
For many years physiologists considered the pineal gland, lodged deep within the brain, a vestigial organ which is merely an anatomical remnant of a primary sensory system. To the clinician the pineal gland, by virtue of ts midline position and calcification, was of interest as a radiological landmark to identify mtracranial space occupying processes The pineal gland attracted scientific attention m 1963, when its primary secretion, melatonin, was first recognized as a hormone. Wurtman and Axelrod (1965) "The pineal gland." Scientific American. 231, 50-60) termed the pineal gland a "neuroendocrme transducer, " an organ which converts neural signals from the external environment such as photic, acoustic, thermic, and magnetic cues into neuroendocrme output which acts on the nervous system largely via the secretion of its principal hormone melatonin.
The pineal gland is unique among endocrine organs for a number of reasons: (1) it is one of the few unpaired endocrine organs, (2) on a weight basis, it receives one of the richest blood supplies of any organ; (3) it lies outside the blood brain barrier, but has direct access to the cerebrospmal fluid (CSF) via the third ventricle; (4) it produces and/or contains high concentrations of a number of different mdoleamines and low molecular weight peptides of probable endocrine importance, ana (5) it is responsive to changes in magnetic field strength and to external electrical stimuli (Foley et al. (1986) "Pineal mdoles : significance and measurement " Neuroscience & Biobehavioral Reviews, 10, 273-293) . Over the past several years scientists have come to suspect that melatonin is a "master hormone" involved m the control of circadian rhythms (biological cycles that recur at approximately 24-hour intervals) , and protecting against common diseases of aging. Melatonin is now recognized to exert an important influence on a host of biological functions including synchronization of biological rhythms, stabilization of neuronal activity, regulation of sexual maturation and reproduction, immunomodulation, temperature control, sleep, mood, appetite, pain control, cognitive functions, and motor behavior (Ehrlich and Apuzzo (1985) "The pineal gland: anatomy, physiology, and clinical significance." Journal of Neurosurgerv, 63, 321-341; Rel in (1966) "The pineal gland." New England Journal of Medicine, 274, 944-949; Reiter (1991) "Pineal melatonin: cell biology of its synthesis and of its physiological interactions." Endocrine Reviews, 12, 151-180; Datta and King (1980)
"Melatonin: effects on brain and behavior " Neuroscience & Biobehavioral Reviews, 4, 451-458, Anton-Tay (1974) "Melatonin effect on brain function." Advances m Biochemical Psychopnar acology, 11, 315-324; Cagnacci et al. (1994) "Melatonin-induced decrease of body temperature m women- a threshold event." Neuroendocrmology, 60, 549-552; Chuang et al . (1993) "Melatonin decreases brain serotonin release, arterial pressure and heart rate rats." Pharmacology, 47, 91-97, Armstrong and Redman (1991) "Melatonin: a chronobiotic with antiagmg properties?" Medical Hypotheses, 34, 300-309; Reiter (1992) "The ageing pineal gland and its physiological consequences." BioEssays, 14, 169-175; Trentini et al . (1991) "Pineal gland and aging." Aging, 3, 103-116; Drew and Batt (1972) "A contribution to the evolutionary theory of dreaming: an hypothesis on the role of the pineal gland m species and specimen protection." Biological Psychiatry, 4, 131-146; Bubenik and Pang (1994) "The role of serotonin and melatonin m gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonm-melatonin feedback " Journal of Pineal Research, 16, 91-99) .
In experimental animals pinealecto y (i.e., removal of the pineal gland) results in a syndrome of deficits which include disruption of circadian rhythms and sleep phases, facilitation of a narcoleptic-type REM sleep distribution, increased susceptibility to epileptic seizures, facilitation of abnormal orofacial involuntary movements, decreased tolerance to heat, impairment of opioid analgesia, reduction in brain neurotransmitter levels such as serotonin and GABA, delayed brain maturation, impaired electrolyte balance specifically sodium, calcium and phosphorus metabolism, arterial nypertension, increased plasma cortisol levels, disruption of adrenomedullary diurnal catecholamine synthesis, a biochemical diabetes-like state, elevation of blood cholesterol levels, disruption of circadian rhythms of gonadotropms and testosterone with resultant enlargement of the prostate, impaired wound healing, and promotion of cancer growth due to disruption of immunomodulation and reduced ability to protect cell membranes from peroxidative damage (Armstrong and Redman (1991) "Melatonin: a chronobiotic with antiagmg properties?" Medical Hypotheses, 34, 300-309; Aldegunde et al . (1985) "Effects of pinealectomy on regional brain serotonin metabolism." International Journal of Neuroscience, 26, 9-13; Cunnane et al . (1979) "The pineal gland and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis, roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes." Medical Hypotheses, 5, 403-407, Kincl et al .
(1970) " Observation on the influence of changing photoperiod on spontaneous wheelrunn g activity of neonatally pmealectomized rats." Endocrinology, 87, 38-42, Banerji and Quay (1976) "Adrenal dopamine beta-hydroxylase activity: twenty four hour rhythmicity and evidence for pineal control." Experientia, 32, 253-255, Csaba and Barth (1974) "The effect of pinealectomy on the perifollicular cells of the rat thyroid gland." Acta
Anatomica, 88, 137-146; Kinson and Peat (1971) " The influences of illumination, melatonin and pinealectomy on testicular function m the rat." Life Sciences, 10, 259-269 , Shirama et al . (1982) "Influence of pinealectomy on circadian patterns of plasma lutemiz g hormone, follicle-stimulating hormone, testosterone and dihydrotestosterone in the male rat . " Journal of Enαocnnological Investigations, 5, 397-401, Milcu et al .
(1971) "The effect of pinealectomy on plasma insulin in rats." In G.E.W. Wolstenholme and J. Knight (Eds.) , The pineal gland (pp. 345-360) . London:Churchill Livingstone; Diaz and Blazquez (1986) "Effect of pinealectomy on plasma glucose, insulin and glucagon levels in the rat." Hormone Metabolic Research, 18, 225-229; Zanoboni and Zanoboni-Muciaccia (1967) "Experimental hypertension in pmealectomized rats." Life Sciences, 6, 2327- 2331; Holmes and Sugden (1976) "The effect of melatonin on pinealectomy-induced hypertension in the rat." British Journal of Pharmacology, 56, 360-361; Karppanen et al . (1970) "Studies with pmealectomized rats." Pharmacology, 3, 76-84; Kavaliers et al . (1983) "Ageing, opioid analgesia and the pineal gland." Life Sciences, 32, 2279-2287; Kumar et al . (1982) "Diurnal fluctuations methionme-enkephalm levels in the hypothalamus and preoptic area of the male rat. effects of pinealectomy." Neuroendocrinology, 35, 28-31; N r et al . (1969) "Changes in the electrical activity of the brain following pinealectomy." Neuroendocrinology, 4, 122-127; Kamback et al . (1982) "Effect of pinealectomy on fatty acid composition of rat brain myelin." Endocrinology, 110, 907-909; Reiter et al . (1973) "Nature and time course of seizures associated with surgical removal of the pineal gland from parathyroidectomized rats." Experimental Neurology, 38, 386-397; Mouret et al . (1974) "Effet de la pmealectomie sur les etats et rythmes de sommeil du rat male. Brain Research, 81, 97-105; Oxenkrug et al . (1984) "Effects of pinealectomy and aging on the serum corticosterone circadian rhythm in rats." Journal of Pineal Research, 1, 181-185; Sandyx. and Fisher (1989) "Increased incidence neuroleptic- duced movement disorders pmealectomized rats." International Journal of Neuroscience, 48, 303-308; Heldmaier and Lynch (1986) "Pineal involvement m thermoregulation and acclimatization." Pineal Research Reviews, 4, 97-139; Pieri et al . (1994)
"Melatonin:a peroxyl radical scavenger more effective than vitamin E." Life Sciences, 55, PL271-276; Lapm and Ebels (1981) "The role of the pineal gland in neuroendocrme control mechanisms of neoplastic growth." Journal of Neural Transmission, 50, 275-282; Romijn (1978) "The pineal a tranquillizing organ?" Life Sciences, 23, 2257-2274) .
Many of the disease conditions associated with aging such as sleep and cognitive disorders, mental depression, disruption of the circadian rhythms of pituitary hormone secretion, obesity, hypertension, atherosclerosis, osteoporosis, hyper- cholesterolemia, glucose intolerance, ionic imbalance, endocrine changes (i.e., decrease plasma gonadotropin and growth hormone levels) and gastrointestinal disorders (i.e., bowel constipation) , are thought to be related to or associated with the gradual decline in the secretory activity of the pineal gland with aging with resultant disorganization of circadian rhythms (Brown et al . (1979) "Melatonin in human cerebrospmal fluid in daytime; its origin and variation with age." Life Sciences, 25, 929-936, Iguchi et al . (1982) " Age-dependent reduction in serum melatonin concentrations m healthy human subjects." Journal of Clinical Endocrinology and Metabolism, 55, 27-29; Nair et al . (1986) "Plasma melatonin - an index of brain aging m humans?" Biological Psychiatry, 21, 141-150; Sack et al . (1986) "Human melatonin production decreases with age." Journal of Pineal Research, 3, 379-388; Sandyk et al . (1992) "Is Postmenopausal osteoporosis related to pineal gland functions?" International Journal of Neuroscience, 62, 215-225; Birau (1981) "Melatonin human serum: progress in screening investigation and clinic." In Birau N. and Shloot W. (Eds.) , Melatonin:current status and perspectives (pp. 297- 326) .Oxford:Pergamon Press; Barnes et al . (19741 "Insulin resistance, skin changes, and virilization: a recessively inherited syndrome possibly due to pineal gland dysfunction." Diabetologia, 10, 285-289." Tasca et al . (1974) "Disappearance of aortic lesions in the rabbits with experimental atheromatosis after pineal extraction administration." Revue Roumanian d' Endocrinologie, 11, 209-213; Ostroumova and Vasiljeve (1976) " Effect of polypeptide pineal extract on fat-carbohydrate metabolism." Problems in Endocrinology, 22, 66-69; Muller-
Wieland et al . (1994) "Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes." Biochemical and Biophysical Research Communications, 203, 416-421; Trentini et al . (1991) "Pineal gland and aging." Aging, 3 103-116; Grad and Rozencwaig (1993) "The role of melatonin and serotonin in aging:update . " Psychoneuroendocrinolgy, 18, 283-295; Armstrong and Redman (1991) "Melatonin:a chronobiotic with antiaging properties?" Medical Hypotheses, 34, 300-309; Reuss et al . (1986) "Electrophysiological and endocrinological aspects of aging in the rat pineal gland." Neuroendocrinology, 43, 466-470; Thomas and Miles (1989) "Melatonin secretion and age." Biological Psychiatry, 25, 365-367; Wetterberg (1983) "The relationship between the pineal gland and the pituitary-adrenal axis in health, endocrine and psychiatric conditions."
Psvchoneuroendocrinology, 8, 75-80; Touitou et al. (1984) "Patterns of plasma melatonin with ageing and mental condition: stability of nyctohemeral rhythms and differences in seasonal vatriatons." Acta Endocrinologica, 106, 145-151; Copinschi and Van Cauter (1994) "Pituitary hormone secretion in aging: roles of circadian rhythmicity and sleep." European Journal of Endocrinology, 131, 441-442) .
In fact, in recent years, melatonin has been considered an anti-aging hormone and the hypothesis has been put forward that aging is secondary to pineal failure (Walker et al . (1978)
"Pineal gland structure and respiration as reflected by age and diet." Experimental Gerontology, 13, 91-99; Rozenchwaig et al . (1987) "The role of melatonin and serotonin in aging." Medical Hypotheses, 23, 337-352; Sandyk (1990) "Possible role of pineal melatonin in the mechanisms of aging " International Journal of Neuroscience, 52, 85-92; Grad and Rozencwaig (1993) "The role of melatonin and serotonin m aging.update. Psychoneuroendocrmology, 18, 283-295; Pierpaoli et al . (1990) "Aging-postponing effects of circadian melatonin: experimental evidence, significance and possible mechanisms." International Journal of Neuroscience, 51, 339-340, Pierpaoli (1991) "The pmeal gland:a circadian or seasonal aging clock?" Aging, 3, 99-101; Lesnikov and Pierpaoli (1994) "Pmeal cross transplantation (old-to-young and vice versa) as evidence for an endogenous "aging clock." Annals of the New York Academy of Sciences, 719, 456-460; Sharma et al . (1989) "Circadian rhythms of melatonin and cortisol aging." Biological Psychiatry. 25, 305-319; Stokkan et al . (1991) "Food restriction retards aging of the pineal gland." Brain Research, 545, 66-72; Laudon et al
(1988) " Melatonin receptors discrete brain areas of the male rat Impact of aging on density and on circadian rhythmicity. " Neuroendocrinology, 48, 577-583; Reiter et al . (1980) "P eal melatonin rhythm:reduction in aging Syrian hamsters " Science. 210, 1372-1373) . Moreover, it has been suggested that the pmeal gland regulates the necessary genetic switching occurring m the cells throughout the body which cause the aging process (Kloeden et al . (1990) "Does a centralized clock for ageing exist?" Gerontology, 36, 314-322) . According to this hypothesis aging is a process related tc melatonin deficiency as ablation of the p eal gland in rodents produced pathological changes resembling senescence which are reversed by the administration of a p eal extract or melatonin (Malm et al . (1959) "The effect of pinealectomy on bodily growth, survival rate and P32 uptake in the rat." Acta
Endocrmologica, 30, 22-28; Dilman et al. (1979) "Increase in life span in rats following polypeptide pmeal extract treatment." Experimental Pathology, 17, 539-545, Pierpaoli and Maestroni (1987) "Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-agmg effects " Immunology
Letters, 16, 355-362) . Moreover, senescence is also inhibited and life span is prolonged when the pineal glands of young mice are grafted mto old animals (Pierpaoli et al . (1991) "The p eal control of aging: the effects of melatonin and p eal graftmg on the survival of older mice " Annals of the New York Academy of Sciences, 621, 291-313; Pierpaoli and Regelson (1994) "Pmeal control of aging: effect of melatonin and p eal grafting on ag g mice . " Proceedings of the National Academy of Sciences, USA, 91, 787-791; Walker et al . (1978) "Pmeal gland structure and respiration as affected by age and hypocaioπc diet." Experimental Gerontology, 13, 91-99) .
One of the mechanisms by which melatonin acts as an anti¬ agmg hormone is through the promotion of the release of growth hormone (Martin (1976) "Pathophysiology of growth hormone regulation." In Martini and Ganong (Eds.) , "Frontiers in neuroendocrinology" (pp.129-168) New York:Raven Press; Smythe and Lazarus (1974) "Growth hormone responses to melatonin in man." Science, 1984, 1373; Petterborg et al . (1991) "Effect of melatonin replacement on serum hormone rhythms m a patient lacking endogenous melatonin." Brain Research Bulletin, 27, 181- 185) . Growth hormone secretion declines dramatically with agmg accounting for several features associated with agmg such as memory loss, obesity, decreased motor activity, increased incidence of sleep disturbances, and increased susceptibility to hypothermia (Plum and van Uitert (1978) "Nonendocrine diseases and disorders of the hypothalamus." In Reichlm et al (Eds.) , "The Hypothalamus" (pp. 415-473) New York:Raven Press; F kelstem et al. (1972) " Age-related change m the twenty- four hour spontaneous secretion of growth hormone." Journal of Clinical Endocrinology and Metabolism, 35, 665-670; Carlson et al. (1972) " Absence of sleep related growth hormone peaks aged normal subjects and in acromegaly." Journal of Clinical Endocrinology and Metabolism 34, 1102-1105; Van Coevorden et al . (1991) "Neuroendocrme rhythms and sleep agmg men." American Journal of Physiology, 260, E651-661) .
The clinical consequences of melatonin deficiency include, among others, decrease in cerebral energy metabolism with decline m memory and other cognitive functions, tendency to depressive mood, decline in the percentage of alpha brain waves, deterioration of sleep efficiency with increased number of nocturnal awakenings, increased daytime sleepiness, diminished immune functions with increased probability of cancer and autoimmune diseases, deterioration of metabolic and endocrine homeostasis, impaired gastrointestinal motility, susceptibility to the development of psoriasis, acceleration of atherosclerosis, poor wound healing, and decreased longevity (Reiter, R.J. (1992) "The ageing pmeal gland and its physiological consequences." BioEssaγs, 14, 169-175, Okawa et al (1994) "Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia " Acta Psychiatrica Scandmavica, 89, 1-7; Birau and Schloot (1979) "Pathological nyctohumeral rhythm of melatonin secretion in psoriasis " IRCS Medical Science, 7, 400, Lieberman (1986) "Behavior, sleep and melatonin." Journal of Neural Transmission, 21 (suppl) , 233-241, Bartsch et al . (1981) "Urinary melatonin levels in human breast cancer patients." Journal of Neural Transmission, 52, 281-294, Tamarkm et al . (1982) "Decreased nocturnal plasma melatonin peak patients with estrogen receptor positive breast cancer " Science, 216, 1003-1005; Haimov et al . (1994) "Sleep disorders and melatonin rhythms in elderly people " British Medical Journal , 309, 167; Miles and Philbrick (1988) "Melatonin and psychiatry." Biological Psychiatry, 23, 405-425; Pavel et al . (1980) "Vasotocm, melatonin and narcolepsy possible involvement of the pineal gland in its pathophysiological mechanism." Peptides, 1, 281-284; Rozencwaig et al (1987) "The role of melatonin and serotonin in agmg." Medical Hypotheses, 23, 337-352; Armstrong and Redman (1991) "Melatonin- a chronobiotic with antiagmg properties?" Medical Hypotheses. 34, 300-309)
Melatonin has been considered a chronobiotic hormone, i.e., a hormone that can act as a synchronizer or "Zeitgeber" to reset the phase of biological rhythms by acting on the circadian pacemaker in the suprachiasmatic nucleus of the hypothalamus (Armstrong and Redman (1991) "Melatonin: a chronobiotic with antiagmg properties?" Medical Hypotheses, 34, 300-309) . Consequently, diminished pineal melatonin functions may result in the disruption of biological rhythms of numerous biochemical, physiological, hormonal, and behavioral systems leading to disease and ag g (Armstrong and Redman (1991) "Melatonin: a chronobiotic with anti-aging properties7" Medical Hypotheses, 34, 300-309; Ingram et al . , (1982) "Circadian rnythmicity and sleep:effects of agmg in laboratory animals " Neurobiology of Agmg, 3, 287-297, Van Gool et al . (1987) "Age-related changes in circadian sleep-wakefullness rhythms m male rats isolated from time cues." Brain Research, 413, 384-387)
Since melatonin is a chronobiotic hormone it may be used therapeutically to re-entra short-term dissociated or long- term desynchronized circadian rhythms or physiologically prevent their disruption following environmental msult and thus correct many of the pathological conditions which are associated with p eal failure associated with agmg For instance, the fact that melatonin administered to humans alleviates the deleterious effects of jet-lag, prolongs deep stages of sleep (i.e., restores youthful sleep patterns) and improves mood (Arendt et al. (1987) "Some effects of jet-lag and their alleviation by melatonin." Ergonomics, 30, 1379; Kales and Kales (1974) "Sleep disorders: recent findings the diagnosis and treatment of disturbed sleep." New England Journal of Medicine, 290, 487- 499; Haimov et al . (1994) "Sleep disorders and melatonin rhythms in elderly people." British Medical Journal, 309, 167) supports its chronobiotic properties as are the findings that bright light, which synchronizes biological rhythms, improves sleep and behavior disorders the elderly and patients with Alzheimer's dementia (Okawa et al . (1994) "Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia " Acta Psychiatrica Scandmavica, 89-1-7, Satlm et al. (1992) "Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease." American Journal of Psychiatry, 149, 1028-1032) and the findings that melatonin extends the life span experimental animals (Pierpaoli and Maestroni (1987) "Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects." Immunology Letters, 16, 355-362; Pierpaoli and Regelson (1994) "Pineal control of ag g: effect of melatonin and p eal grafting on aging mice. " Proceedings of the National Academy of Sciences. USA, 91, 787-791) . I believe that one of the mechanisms by which melatonin acts as an anti-aging hormone is through the promotion of the release of growth hormone. Growth hormone is an anabolic hormone which stimulates protein synthesis, bone growth and glucose metabolism. In addition, it promotes inhibition of fat formation and causes improved sleep energy, enhancement of immune functions, and stimulation of nerve growth factors (Quabbe (1985) "Hypothalamic control of GH secretion:pathophysiology and clinical implications." Acta Neurochirurgica, 75, 60-71; Astrom and Trojaborg (1992) "Effect of growth hormone on human sleep energy. " Clinical Endocrinology, 36, 241-245; Rusovan and Kanje (1992) "Magnetic fields stimulate peripheral nerve regeneration in hypophysectomized rats." NeuroReport, 3, 1039-1041) . The secretion of growth hormone from the pituitary gland particularly during sleep declines gradually with aging thus accounting for several features associated with aging such as decreased protein synthesis, bone loss, decline in immune functions, decline in the activity of nerve growth factors, progressive memory loss, obesity, decreased motor activity, increased incidence of sleep disturbances and increased susceptibility to hypothermia (Meites (1986) "The neuro¬ endocrinology of hypothalamic aging." In Muller E.E. and MacLeod, R.M. (Eds.) , Neuroendocrine perspectives, vol. 5 (pp. 179-189) . Amsterdam: Elsevier,- Plum and van Uitert (1978)
"Nonendocrine diseases and disorders of the hypothalamus" In Reichlin et al. (Eds.) , "The hypothalamus" (pp. 415-473) New York:Raven Press; Van Coevorden et al . (1991)" Neuroendocrine rhythms and sleep in aging men." American Journal of Physiology. 260, E651-661) .
It is my belief based on my knowledge in the field, that the anti-aging effect of the pulsed magnetic field is enhanced by prior administrations of agents which promote growth hormone release. Thus my present invention additionally includes administering an effective amount of an agent which promotes growth hormone release prior to application of the AC pulsed magnetic field. The amino acids L-arginine and L-ornithine both stimulate the release of growth hormone in humans (Martin and Reichlin (1987) "Regulation of growth hormone secretion and its disorders" In Clinical neuroendocrinology (p. 237) F.A. Davis: Philadelphia) .
In addition to the ambient light/dark cycle, the activity of the pineal gland and hence the rate of melatonin secretion is influenced also by the earth's geomagnetic field which is in the order of 30,000 - 60,000 nanotesla (0.3 - 0.6 Gauss) The earth's magnetic field is primarily a nontime-varymg (DC) field with angle of incidence to the earth's surface increasing with increasing latitude. For comparison, anthropogenic magnetic fields are primarily time varying at 50 or 60 Hz and harmonic of these frequencies. Typical magnetic fields measured m residential settings range from 0.1 microtesla to 3 microtesla at 60 Hz frequency. The geomagnetic field has been a part of the environment throughout the evolution of animals and is used by certain species m their adaptive strategies Organisms are capable of perceiving its intensity, polarity, and direction (Gould (1984) "Magnetic field sensitivity animals." Annual Review of Physiology, 46, 585-598) . It is thought that the circadian rhythmicity of the earth's magnetic field may have an additional "Zeitgeber" (time cue) function m the organization of biological rhythms (Cremer-Bartels et al. (1984) "Magnetic field of the earth as additional zeitgeber for endogenous rhythms'5" Naturwissenschaften, 71, 567-574, Wever (1968) "Emfluss Schwacher Elektro-magnetischer Felder auf die Circadiane Periodik des Menschen " Naturwissenschaften, 55 , 29- 32; Bartsch et al . (1994) "Seasonality of pmeal melatonin production in the rat: possible synchronization by the geomagnetic field." Chronobiology International , 11, 21-26) .
Since the activity of the pmeal gland is sensitive to the influences of the geomagnetic field it has been suggested that it functions as a agnetoreceptor as well (Sem et al <1980) "Effects of an earth-strength magnetic field on electrical activity of pineal cells." Nature, 288, 607-608; Semm (1983) "Neurobiological investigations on the magnetic sensitivity of the p eal gland in rodents and pigeons " Comparative
Biochemistry and Physiology, 76A, 683-689; Olcese et al. (1988) "Geomagnetic field detection in rodents." Life Sciences. 42, 605-613; Demame and Semm (1985) "The avian pmeal gland as an mdependent magnetic sensor." Neuroscience Letters, 62, 119- 122; Rudolph et al. (1988) "Static magnetic fields decrease nocturnal p eal cAMP in the rat." Brain Research. 446, 159- 160) Based on histological studies and electrophysiological single unit recordings from the pineal gland of rodents and pigeons, it has been estimated that 20%-30% of p eal cells respond to magnetic fields (Semm (1983) "Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons." Comparative Biochemistry and Physiology, 76A, 683-689) . Electrophysiological studies by Reuss et al. ((1983) "Different types of magnetically sensitive cells in the rat pmeal gland" Neuroscience Letters, 40, 23-26) have demonstrated the presence of different types of magnetically sensitive cells the pmeal gland of the rat.
Furthermore, short-term exposure of experimental animals to magnetic fields of various intensities has been shown to alter temporarily the secretion of melatonin while more chronic exposure may even induce ultrastructural morphological changes the pineal gland (Bardasano et al (1985) "Ultrastructure of the pineal cells of the homing pigeon Columba livia and magnetic fields (first trials) ." Journal Fuer Hirnforschung, 26, 471- 475; Semm et al. (1980) "Effects of an earth-strength magnetic field on electrical activity of pineal cells." Nature, 288 607- 608; Welker et al. (1983) "Effects of an artificial magnetic field on serotonin N-acetyltrans erase activity and melatonin content of the rat pmeal gland." Experimental Brain Research 50, 426-432; Wilson et al. (1981) "Neuroendocrine mediated effects of electromagnetic field exposure: possible role of the pineal gland." Life Sciences, 45, 1319-1332)
The human pmeal gland, likewise, is believed to be sensitive to changes in the environmental magnetic fields. Howard et al . ((1965) "Psychiatric ward behaviour and geophysical parameters." Nature, 205, 1050-1052) made the seminal observations of a relationship between increased geomagnetic activity and the rate of admission of patients to psychiatric facilities. Ra aram and Mitra (1981) "Correlation between convulsive seizure and geomagnetic activity." Neuroscience Letters, 24, 187-191 and Venkatraman ((1976) "Epilepsy and solar activity. An hypothesis." Neurology (India) , 24, 1-5) reported an association between changes in the geomagnetic field due to magnetic storms and frequency of seizures in epileptic patients. Semm (1992) "Pineal function m mammals and birds is altered by earth-strength magnetic fields." In Moore-Ede, Campbell, and Reiter (Eds.) , Electromagnetic Fields and Circadian Rhythmicity, (pp. 53-62) , Birkhauser. Boston) observed in normal subjects placed in the center of a Helmholtz coil system that inversion of the horizontal component of the ambient magnetic field for 30 minutes at midnight resulted in a significant (70%) depression of plasma melatonin concentrations.
In addition to melatonin and light,human circadian rhythms may be synchronized by magnetic fields. For instance, there is increasing evidence that the earth's magnetic field, which also undergoes diurnal and seasonal variations (Cremer-Bartels et al (1984) "Magnetic field of the earth as additional zeitgeber for endogenous rhythms?" Naturwissenschaften, 71, 567-574) , provides a "Zeitgeber" (time cue) for the synchronization of endogenous circadian rhythms in mammals and humans (Wever) (1968) "Einfluss schwacher elektro-magnetischer felder auf die circadiane Periodik des Menschen." Naturwissenschaften, 55, 25- 32; Bliss and Heppner (1976) "Circadian activity rhythms influenced by near zero magnetic field." Nature , 261, 411-412) for instance, Wever (1968) "Einfluss schwacher eiektro- magnetischer felder auf die circadiane Periodik des Menschen." Naturwissenschaften, 55, 29-32) demonstrated that shielding of the ambient magnetic fields significantly desynchronized human circadian rhythms . Individuals placed in an underground bunker showed gradual desynchronization and lengthening of circadian rhythms, which could be resynchronized when an artificial 10-Hz, 25-mV/cm magnetic field was applied under similar conditions. Thus, it is thought that the circadian rhythmicity of the earth's magnetic field may have an additional "Zeitgeber" function in the organization of biological rhythms (Cremer- Bartels et al . (1984) "Magnetic field of the earth as additional zeitgeber for endogenous rhythms?" Naturwissenschaften, 71, 567-574) . The effect of magnetic fields on human circadian rhythms is supported also by the observation epileptic patients in whom treatment with picotesla range pulsed magnetic fields was shown to alter the circadian periodicity of seizures (Sandyk and Ann os (1992) "Magnetic fields alter the circadian periodicity of seizures." International Journal of Neuroscience, 63, 265-274) .
The synchronizing effects of magnetic fields on circadian rhythms is mediat ^d largely via the pmeal glanα which serves as a magnetoreceptor organ (Semm et al . (1980) "Effects of an earth-strength magnetic field on electrical activity of pineal cells." Nature, 288, 607-608; Semm (1983) "Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons." Comparative Biochemistry and
Physiology, 76A, 683-689; Olcese et al . (1988) "Geomagnetic field detection in rodents." Life Sciences, 42, 605-613; Welker et al . (1983) "Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland." Experimental Brain Research, 50, 426- 432) . Experimental data indicate that exposure of animals and humans to magnetic fields is associated with a temporary inhibition of melatonin secretion (Welker et al . (1983) "Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland."
Experimental Brain Research, 50, 426-432; Wilson et al . (1986) "60-Hz electric-field effects on pineal melatonin rhythms: time course for onset and recovery." Bioelectromagnetics , 7, 239- 242) . However, with termination of magnetic fields exposure melatonin plasma levels usually return to their preexposure level and may even rise to higher levels over the following hours as shown by experiments performed by the inventor with subjects exposed nocturnally to picotesla range intensity magnetic fields (unpublished data) . These changes in pineal melatonin functions in response to magnetic fields exposure are thought to induce significant biological effects through a process involving the synchronization of the biological rhythms including those of hormone release as well as neurotransmitter synthesis and release. Since melatonin is a "master hormone" involved in the programming of the aging process and as aging is associated with pineal failure and administration of melatonin or pineal extracts prolongs life span in experimental animals, I believe that activation of the pineal gland by periodic application of pulsed magnetic fields may be used to retard the aging process and therapeutically to improve pathological states which are linked to or result from pineal failure due to aging such as sleep disturbances, loss of memory functions, disturbances of behavior, and depressive mood. This is supported by the observations that pulsed magnetic fields have been shown in normal elderly subjects to alleviate the deleterious effects of jet-lag (1 e , fatigue, malaise) , improve sleep efficiency, restore dream recall, increase level of energy and improve mood, promote relaxation, improve level of concentration, enhance sexual functions, improve bowel functions with resolution of constipation, normalize previously mcreaseα plasma levels of cholesterol, normalize previously elevated blood glucose levels, normalize previously elevated blood pressure, dimmish the activity of psoriatic skin lesions, and enhance immune functions (i.e , prevent exacerbation of herpes infection; dimmish frequency of influenza infections) . The most dramatic effects of pulsed magnetic fields m normal adult and elderly subjects mcluded improvement in sleep, mood, behavior (agitation and impulsive aggressive behavior) , and short-term memory functions.
In patients with Parkinson's disease and Alzheimer's disease, which are both diseases of agmg (Knoll (1990) "Nigrostriatal dopaminergic activity, deprenyl treatment and longevity." In Streifler et al. "Advances m neurology
Parkinson's disease: anatomy, pathology and therapie . " New York: Raven Press; Langston (1988) "Agmg, neurotoxins, and neurodegenerative disease. "In R.D. Terry (Ed.) , Agmg and the brain (pp. 149-164) New York : Raven Press) , application of AC pulsed magnetic fields once to twice per week has been shown to improve sleep efficiency, abolish nocturnal awakenings, restore dream recall, improve short-term memory functions, improve concentration and level of energy, restore alpha brain wave activity on the EEG record (which is diminished with agmg) , enhance sexual functions, improve gastrointestinal functions (i.e , constipation) , dimmish the extent of psoriatic skin lesions, normalize previously recorded high blood pressure, and increase plasma growth hormone, lute izmg hormone (LH) and testosterone levels (Sandyk (1992) "Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon." International Journal of Neuroscience, 66, 97-106, Sandyk and Derpapas (1993) "Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease " International Journal of Neuroscience, 69, 167-183, Sandyk (1995) "Improvement in short-term visual memory by weak electromagnetic fields m Parkinson's disease." International Journal of Neuroscience, 81, 67-82; Sandyk and Derpapas ,1993) "The effects of external picotesla range magnetic fields on the EEG Parkinson's disease." International Journal of Neuroscience, 70, 85-96; Sandyk (1994) "A drug naive Parkmsonian patient successfully treated with electromagnetic fields." International Journal of Neuroscience, 79, 99-110; Sandyk (1994) "Alzheimer's disease: Improvement of visual memory and visuoconstructive performance by treatment with picotesla range magnetic fields." International Journal of Neuroscience, 76, 185-225; Sandyk (1994) "The effects of external picotesla range magnetic fields on the EEG in Parkinson's disease: a follow up study." International Journal of Neuroscience, 76, 227-229) , features which are consistent with the notion that pulsed magnetic fields improve age-related disturbances linked to pmeal failure. These therapeutic effects appeared to be significantly augmented when pulsed magnetic fields were administered m conjunction with my pharmacological-nutritional composition described m my parent application Serial No. 181,677 and my continuation-m-part thereof filed concurrently herewith (RSI) . The use of my composition is important because the therapeutic efficacy of externally applied magnetic fields, as described m the prior art, is limited by several factors:
(a) The pmeal gland tends to undergo an increased rate of calcification with age and particularly in association with various systemic disorders (Trentmi et al. (1987) "Pineal calcification in different physiopathological conditions in humans." In Trentini et al . Fundamentals and clinics in ineal research (pp. 291-304) New York: Raven Press; Welsh (1985) "Pineal calcification: structural and functional aspects." Pmeal Research Reviews, 3 , 41-68) . It is believed that calcification of the pmeal gland may interfere with its magnetosensitivity. The calcified material which consists of hydroxyapatite and calcium carbonate apatite crystals as well as high concentrations of several trace elements such as iron, magnesium, zmc, copper, and manganese (Humbert and Pevet (1991) "Calcium content and concretions of pmeal glands of young and old rats " Cell and Tissue Research, 263, 593-596) may altei the physicochemical properties of the gland and interfere with the ability of the pmeal glanα to release melatonin m response to magnetic fields,- (b) Reduction the activity of the p eal gland in agmg may be related to various factors including, among others, increased accumulation of agmg pigment in the p ealocytes, decrease m pmeal receptor sensitivity and/or density, decline in the availability of nutritional co-factors for serotonin and melatonin synthesis, decline in the capacity of pineal cells to synthesize serotonin from tryptophan, and decrease sympathetic nervous system activity which provides a stimulus for melatonin syntheses (Tang et al. (1985) "Agmg and diurnal rhythms of pineal serotonin, 5-hydroxymdoleacetιc ac d, norepmephrme, dopamme and serum melatonin m the male rat " Neuroendocrinology, 40, 160-164, Dax and Sugen (1988) "Age- associated changes m pmeal adrenergic receptors and melatonin synthesizing enzymes the Wh star rat " Journal of Neurochemistrv, 50, 468-472 Wildi and Frauchiger (1965) "Modifications histologiques de I'epiphyse humame pendant l'enfance, 1 ' age adulte et le vieillissement " Progress m Brain Research, 10, 218-233) , and
(c) Agmg is associated with diminished serotonin receptor density and cerebral concentrations of serotonin, a precursor of melatonin synthesis. In addition, levels of the ammo-acid tryptophan, a precursor of serotonin synthesis, are reduced the blood of a proportion of elderly people who fail to absorb tryptophan (Ingram et al . (1982) "Circadian rhythmicity and sleep: effects of ag g in laboratory animals." Neurobiology of Agmg. 3, 287-297, Gottfries (1990) "Disturbance of the 5- hydroxytryptamme metabolism in brains from patients with Alzheimer's dementia " Journal of Neural Transmission, 30 (suppl) (33-43) ; Goldman-Rakic and Brown (1981) "Regional changes of monoam es in cerebral cortex and subcortical structures of aging rhesus monkeys " Neuroscience, 6, 177-187, Gross-Isseroff et al (1990) "Autoradiographic analysis of age-dependent changes in serotonin 5-HT-, receptors of the human brain postmortem." Brain Research, 519, 223-227 ;Chen Shih and Young (1978) "The alteration of serotonin binding sites m aged human brain." Life Sciences, 23, 1441-1448; Lehmann, (1979) "How to investigate malabsorption and the value of repeated tryptophan loads. In Schou, M. and Stromgren, E (Eds.) , Origin, prevention and treatment of affective disorders (pp 125-138) London Academic Press) . Brain serotonin deficiency contributes to the development of sleep, mood and memory disturbances in the elderly. Moreover, many of the biological effects of melatonin are mediated via the serotonin system (Smith and Kappers (1975) "Effect of pinealectomy, gonadectomy, pCPA and p eal extracts on the rat parvocellular neurosecretory hypothalamic system: a fluorescence histochemical investigation." Brain Research. 86, 353-371; Anton-Tay et al . (1968) "Brain serotonin concentration- elevation following intraperitoneal administration of melatonin." Science, 162, 277-278; Anton-Tay (1974) "Melatonin:effect on brain function." Advances Biocnemical Psvchopharmacology, 11, 315-324; Olcese (1985) "Enhancement of melatonin 's antigonadal action by daily injections of the serotonin uptake inhibitor fluoxetme m male hamsters." Journal of Neural Transmission, 64, 151-161, Gaffoπ and Van Ree (1985) "Serotonin and antidepressant drugs antagonize elatonm- mduced behavioral change after injection into the nucleus accumbens of rats." Neuropharmacology, 24, 237-244) .
SUMMARY OF THE INVENTION
The present invention relates to the use of a pulsed magnetic field in combination with a pharmacological-nutritional composition to retard the agmg process and improve age-related disease conditions. More particularly, the present invention relates to the enhancement of the activity of the pmeal gland and specifically the production of its principal hormone melatonin which is considered a "master hormone" m the regulation of biological rhythms. The purpose of the composition is to sensitize the p eal gland to the effects of magnetic fields.
My mvention includes a method of retarding the agmg process and improving the symptoms of age-related disease conditions in humans which comprises administering to a human m need thereof an effective amount of a composition which increases serotonin transmission to such human followed py the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform. This composition is preferably supplemented by a dietary composition rich in the ammo-acid tryptophan. Optionally, my invention includes administering an effective amount of an agent which promotes growth hormone release prior to the application of the AC pulsed magnetic field. My invention also includes the above referred to composition for increasing serotonin transmission to humans, which composition may optionally include an effective amount of an agent which promotes growth hormone release.
DETAILED DESCRIPTION
Based on studies I have conducted experimental animals, the data provided m the literature presented above and my medical experience treating elderly people, t appears that aging is related to a decline m pineal melatonin functions and serotonin neurotransmission and that several pathological conditions associated with agmg such as sleep disorders, mood and conduct disturbances such as depression and aggressive behavior, decline in memory functions, rise in blood pressure, impairment of glucose tolerance and the like in elderly, are related to pmeal failure which is part of the agmg process . By periodically stimulating the pineal gland and increasing melatonin production usmg pulsed magnetic fields in the picotesla range intensity, I believe, based on my experience with elderly people, particularly patients with Parkinson's disease, Alzheimer's disease and multiple sclerosis, that one can retard the aging process and can improve conditions related to pineal failure such as sleep and mood disturbances as well as memory functions. To retard the agmg process which is due to diminished pmeal melatonin functions and reduced serotonin neurotransmission, application of an appropriate magnetic field once per week which should preferably consist of two successive AC pulses each of 10 to 15 minutes provides a significant improvement.
More enhanced results, however, are achieved according to my invention by the use of my novel pharmacological-nutritional composition wnich increases serotonin transmission together with the AC pulsed magnetic field as described m more detail herem My composition comprises an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the brain, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors, and is preferably supplemented by an effective amount of a dietary composition rich m the ammo-acid tryptophan.
Plasma melatonin concentrations decline progressively with age with a steeper decline occurring m men at about the age of 50 years while in women a more dramatic decline occurs perimenopausally starting at the age of 45 years (Nair et al . (1986) "Plasma melatonin- an index of brain agmg humans?" Biological Psychiatry, 21, 141-150; Sack et al. (1986) "Human melatonin production decreases with age " Journal of Pmeal Research, 3, 379-388) . Consequently, it is advocated that the procedure to retard the agmg process m men should begin at about the age of 50 while in women the procedure should begin earlier around the age of 45 years coincident with the fall of p eal melatonin production perimenopausally
It is preferred for maximum effect that the AC pulsed magnetic field is applied to the bram of the human in two applications separated by an interval of time. Preferably the duration of the first AC pulsed magnetic field is 10 to 15 minutes The duration of the second AC pulse is also preferably 10 to 15 minutes. It is preferred that the time delay between the application of the first AC pulse and the application of the second AC pulse is 15 to 30 minutes.
Accordmg to one embodiment of my invention, the composition comprises one or more of the following: an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the bram, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors. The effective amount of a dietary composition rich m the ammo-acid tryptophan s a preferred supplement to my composition and comprises including in the diet of the person to be treated various foods wnich are rich tryptophan. My composition may optionally include an effective amount of an agent which promotes growth hormone release
Accordmg to a further embodiment of the present invention, the serotonin precursor is L-tryptophan (L-TP) or L-5 hydroxytryptophan (L-5-HTP) Since serotonin present in tne blood is excluded by the blood bra barrier from entry mto the bram, the administration of precursors such as L-TP or L-5-HTP is used to increase brain concentrations of serotonin (Wurtman and Fernstrom (1975) "Control of bram monoam e synthesis by diet and plasma ammo-acids." The American Journal of Clinical Nutrition, 28, 638-647)
According to a further embodiment of the present invention, the stimulant to facilitate the transport of a serotonin precursor mto the bra is one which facilitates the transport of tryptophan mto the brain. It is preferably vitamin B3, chromium (preferably chromium picolmate) or a mixture thereof Chromium is an essential co-factor to insulin production and action (Rabinowitz et al. (1983) "Effects of chromium and yeast supplements on carbohydrate and lipid metabolism m diabetic men " Diabetes Care, 6, 319-327) Insulin, in turn, facilitates the entry of tryptophan mto the bram by mnibitmg the uptake of the branched chain ammo-acids leucine, lsoleuc e, and valme which compete with tryptophan for entry into the brain (Wurtman and Fernstrom (1976) "Control of bram neurotransmitter synthesis by precursor availability and nutritional state." Biochemical Pharmacology, 25, 1691-1696)
Accordmg to a further embodiment of the present invention the agent to increase plasma tryptophan concentrations is a salicylate. L-tryptophan is usually transported m the blood in a bound or complexed form with the protein albumin. It nas been shown that various salicylates displace tryptophan from its protein binding site with albumin in blood plasma thereby raising the free or unbound tryptophan concentration m the blood The bond-breaking effect exerted by salicylates cn the binding of tryptophan to albumin causes a greater availaoility of free tryptophan for diffusion into the bram (Tagliamonte et al . (1973) "Increase of bram tryptophan and stimulation of serotonin synthesis by salicylate " Journal of Neurochemistrv, 20, 909-912) . While aspirin is the salicylate preferred, any other pharmaceutically acceptable salicylate such as sodium salicylate would serve as well.
Accordmg to a further embodiment of the present invention, the stimulant of serotonin synthesis is preferably vitamin B, , vitamin B2, vitamin B3, vitamin B6, biotm, S- adenosyl ethionine, folic acid, ascorbic acid, magnesium, coenzy e Q10, piracetam or mixtures of two or more thereof.
Accordmg to a further embodiment of the present invention, the stimulant of serotonin release is preferably fenflura me (Fuller (1986) "Pharmacologic modification of serotonergic functions- drugs for the study and treatment of psychiatric and other disorders " Journal of Clinical Psychiatry, 47 (suppl 4) , 4-8) .
Accordmg to a further embodiment of the present invention, the stimulant of serotonin receptors is preferably ergoloid mesylates (Hydergine®) . Hyderg e® has been shown to improve mental alertness and memory functions m normal subjects and those with organic mental deterioration an effect which is related partly to its stimulating properties of serotonin receptors m the brainstem reticular formation (Depoortere et al . (1975) "Neuropharmacological studies on Hydergine." Triangle, 14, 73-79) .
Accordmg to a further embodiment of the present invention, the dietary composition should include foods which are rich the ammo-acid tryptophan such as turkey (4 ounces twice a week) , milk (8 ounces per day of whole, low-fat, or skim) , bananas (1 per day) , nuts (1-2 ounces per day) and dry-roasted sunflower seeds (3-4 ounces per day) .
I prefer the use of L-argmme or L-ornithme as agents to promote growth hormone release. Preferably, these agents would be administered the night before and most preferably one to two hour prior to the application of the AC pulsed magnetic field.
It is preferred that the intensity of the magnetic field be the range of 7.5 - 75 picotesla. The magnetic field is a time varying field with a wave form which is sinusoidal, triangular, trapezoidal, square or a composite thereof
It is preferred that the patient's eyes be smelαed during the application of the AC pulsed magnetic fields The rields are preferably applied to the subject's head using a helmet-like transducer array The helmet-like transducer array preferably comprises an array of coils which are flat or helical
It is preferred that the AC magnetic field frequency is 5Hz-8Hz
For the retardation of the aging process resulting from diminished pmeal melatonin functions and reduced serotonin neurotransmission, it is preferred that the AC pulsed magnetic field is applied to the human head once per week
To improve disorders of sleep, mood, behavior, and memory functions, it is preferred that the AC pulsed magnetic field is applied to the human head once or twice per week
For the treatment of hypertension, it is preferred that the AC pulsed magnetic field is applied once or twice per week to the human head.
For the treatment of hypercholesterolemia, t is preferred that the AC pulsed magnetic field is applied to the human head once or twice per week
For the treatment of glucose intolerance and overt diabetes mellitus, it is preferred that the AC pulsed magnetic field is applied to the human head once or twice per week. For the treatment of loss or diminished libido, it is preferred that the AC pulsed magnetic field is applieα to the human head once or twice per week
For the treatment of bowel constipation, it is preferred that the AC pulsed magnetic field is applied to the human head once or twice per week.
For the treatment of psoriasis vulgaris including psoriatic arthropathy, it is preferred that the AC pulsed magnetic field is applied to the human head once or twice per week.
For the treatment of osteoarthritis, it is preferred that the AC pulsed magnetic field is applied once or twice per week
For the treatment of osteoporosis, it is preferred that the AC pulsed magnetic field is applied once or twice per week.
For the treatment of prostate hypertrophy, it is preferred that the AC pulsed magnetic field is applied once or twice per week .
When an effective amount of an agent which promotes growth hormone release is administered, it is administered prior to application of the AC pulsed magnetic field. Preferred agents are L-arginine or L-ornithine. The agent is preferably administered the night before preferably one to two hours prior to the application of the AC pulsed magnetic field.
It is also preferred that the composition be administered four to eight weeks before the application of the first AC pulsed magnetic field.
It is preferred that the AC pulsed magnetic field is a time-varying field with a waveform which is sinusoidal, triangular, trapezoidal, square or a composite thereof. It is also preferable that the subject's eyes are shielded during the application of each AC pulsed magnetic field. The fields may be applied to the subject's head using a helmet-like transducer array as illustrated in the drawings. The helmet-like transducer array preferably comprises an array of coils which are flat, i.e. two dimensional or helical, i.e. three dimensional.
I find particularly good results achieved according to my invention when the AC pulsed magnetic field is applied at night, preferably after 8:00 p.m. I believe this is because plasma melatonin levels begin to rise after about 8:00 p.m. reaching a peak between midnight and 2:00 a.m. (Waldhauser et al . (1984) "Melatonin in human body fluids: clinical significance" In Reiter, R.J. (Ed.) , The pineal gland (pp. 345-370) New York: Raven Press) . Since pulsed magnetic fields alter circadian melatonin secretion, the optimal response to the magnetic field would be expected to occur at night, the time the pineal gland is maximally active.
My composition which is useful for retarding the aging process and improving age-related disease conditions in humans when administered to a human followed by the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform comprises an effective amount of a composition which increases serotonin transmission to the human and may optionally include an effective amount of an agent which promotes growth hormone release .
Accordmg to one embodiment, my composition comprises one or more of the following: an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the bram, an effective amount of an agent to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors. Preferably, the serotonin precursor is L-tryptophan or L-
5-hydroxytryptophan.
Preferably, the stimulant to facilitate the transport of a serotonin precursor into the bram is vitamin B1( chromium or a mixture thereof . Preferably, the agent to increase plasma tryptophan concentration is a salicylate.
Preferably, the stimulant of serotonin synthesis is vitamin B|, vitamin B2, vitamin B3, vitamin B6, biotm, S- adenosylmethionme, folic acid, ascorbic acid, magnesium, coenzyme QK), piracetam or mixtures of two or more thereof . Preferably, the stimulant of serotonin release is fenfluramme.
Preferably, the stimulant of serotonin receptors is an ergoloid mesylate.
DETAILED DESCRIPTION
According to my present invention, the treatment procedure which I have found to be most effective is when the patient is given my composition supplemented by the dietary composition, beginning 4-8 weeks,pre erably 6-8 weeks, prior to the application of the first AC pulsed magnetic field which pulsed magnetic field is preferably applied m two treatments.
In the initial treatment phase, the patient is given the composition which comprises the stimulants to facilitate the transport of the serotonin precursor mto the bram, an agent which increases plasma tryptophan concentrations, the composition comprising the stimulants of serotonin synthesis, the stimulant of serotonin receptors, and the dietary composition rich in the ammo-acid tryptophan On the night prior to application of the magnetic fields the subject is given a serotonin precursor to augment the synthesis of serotonin and melatonin and an agent to promote the release of growth hormone. For the purpose of increasing serotonin synthesis the inventor recommends a preparation containing the essential ammo-acid tryptophan to be taken at bedtime (L- tryptophan 500 mg-3g, orally) or a preparation containing L-5- hydroxytryptophan (L-5-HTP) (25-50 mg, orally) taken at bedtime. L-tryptophan is the preferred serotonin precursor due to its low side effect profile and low risk of toxicity (Young (1986) "The clinical psychopharmacology of tryptophan " In Wurtman, R.J. and Wurtman, J.J. (Eds.) , Nutrition and the bra (pp. 49-88) , vol 7. New York: Raven Press) . For the purpose of promoting growth hormone release the inventor uses L-argmme or L-ornithme (500 mg-1,000 mg) to be taken at bedtime.
One to two hours prior to application of the first magnetic treatment the patient is given a stimulant of serotonin release For this purpose the inventor uses the drug fenfluramme hydrochloride (Pondim ®; 10-20 mg, orally) . In addition, the subject is given again an agent to promote the release of growth hormone such as L-argmme or L-ornithme (500 mg- 1,000 mg) . The first magnetic pulse is given for a period of 10-15 minutes using an AC frequency of 5Hz-7Hz preferably an AC frequency of 5Hz . After a break of 15-30 minutes, a second magnetic pulse is applied for a period of 10-15 minutes using a higher AC frequency of 7Hz-8Hz. It is my experience that the application of the second AC pulse is extremely beneficial for the treatment of neurological and mental disorders and it is therefore preferred to use a second pulse also in the case where the treatment procedure is applied for retardation of the ag g process and for the treatment of age-related disease conditions.
Best results are obtained when the AC pulsed magnetic field is administered at night, preferably after 8:00 p.m.
The AC pulsed magnetic fields are preferably applied via an external magnetic coil assembly, or transducer. The transducer is constructed of flexible substrate which allows the transducer to be bent and positioned on the head of a patient in the form of a helmet . The transducer is constructed of a set of coils positioned side-py-side m a two-dimensional array In the preferred embodiment of the invention as shown m Figs 1-4, the transducer is constructed of 16 coils arranged a matrix of four rows by four columns, and the area of each coil is preferably 3.14 cm2. When these coils are carrying an electric current, they produce magnetic fields with lines of force parallel to the axes of the respective coils The locations of the coils are such that the resultant magnetic fields are uniform. The produced magnetic fields are alternating and their intensity can be less than approximately 60 microtesla For therapeutic purposes herein, it is preferred to employ magnetic flelds strength m the range of 7 5 to 75 picotesla with an AC frequency in the range of 5Hz-8Hz In the experience of the inventor higher amplitudes of the exposed magnetic fields above 75 picotesla and up to 1,000 picotesla did not provide an additional benefit for patients with neurological and mental disorders and it is believed that amplitudes above 75 picotesla w ll not provide an additional benefit also for subjects undergoing this treatment procedure for retardation of the agmg process and for the treatment of age-related disease conditions.
To maintain the effects of the treatment, "maintenance therapy" is implemented during which time the procedure is repeated once to twice per week. Durmg the period of "maintenance therapy" the subject continues to take the pharmacological-nutritional composition except for the compositions which are administered the night before (i.e., L-tryptophan and L-argmme) and ust prior to the application of magnetic fields (i.e., fenfluramme and L-argmme) It is recommended that during the period of "maintenance therapy" the subject should spend at least one hour daily outdoors to maximize sunlight exposure to enhance serotonin functions and synchronize melatonin circadian rhythms (Wurtman and Wurtman (1989) "Carbohydrates and depression." Scientific American, January, 68-75) . Durmg the "maintenance therapy" the subject may continue to receive medications for his/her particular disease. For instance, in the case of hypercholesterolemia the subject may continue to use his cholesterol lowering drugs while receiving the composition and the magnetic field therapy In some instances, such as m the case where this treatment procedure produced normalization of blood pressure antihypertensive drugs may be reduced or discontinued based on prior consultation with a physician With reference to Figs. 1-4, there is shown a transducer 30 which s employed m the practice of the invention to apply magnetic fields upon the bra of a patient The transαucer 30 comprises a set of coils 32, and is placed on the head of a patient 34 Upon energization of the coils 32 with electric current, the coils 32 produce magnetic fields which are directed into the bra , and particularly mto the area of the pmeal gland, of the patient 34 The patient 34 holds a cup 36 to demonstrate the inventive feature of ingesting various pharmacological and nutritional components of the composition prior to application of the magnetic fields Electric current is applied to the coils 32 by a driver 38, the driver 38 including a voltage generator 40 and an output resistor 42 by which the generator 40 is coupled to the coils 32 Also mcluded in the driver 38 is a timer 44 for activating the generator 40 to provide a sequence of pulses of output voltage which are applied to the resistor 42 The resistor 42 has a resistance of approximately 0 5 megohm in the preferred embodiment of the invention, and the coils 32 are connected in series to provide a total resistance of approximately one ohm between the terminals 46 and 48 of the transducer 30 A volt meter 50 is connected between output terminals 52 and 54 of the generator 40 to provide an indication of the magnitude of the output voltage of the generator 40
The coils 32 and the resistor 42 constitute a series circuit between the terminals 52 and 54 of the generator 40
Since the internal impedance of the driver 38, as provided by the resistor 42, is several orders of magnitude greater than that of the transducer 30, the voltage generator 40 m combination with the resistor 42 acts as a current source to provide a current to the transducer 30 proportional to the voltage outputted by the generator 40 In view of the current- source function of the driver 38, the meter 50 also provides an indication of the magnitude of the current flow in the coils 32 of the transducer 30. The intensity of the magnetic fields produced by the current in the coils 32 is proportional to the magnitude of the current and, accordingly, the reading cf the meter 50 serves also as an indication of the intensity of the magnetic fields applied by the transducer 30 to the patient 34. The generator 40 is of well-known construction and provides a voltage with a periodic waveform. The generator 40 includes controls for selecting the AC frequency of the voltage, the waveform of the voltage, and the amplitude of the voltage. By way of example, the voltage may be a steady DC voltage, or may be varied in frequency over a range of 0.1 Hz to 10,000 Hz. The waveform may be sinusoidal, triangular, trapezoidal, square or a combination of more than one of these waveforms such as the sum of square plus sinusoid as shown in Fig. 5, by way of example.
The transducer 30 comprises a substrate 56 which supports the coils 32 in their respective positions in a two-dimensional array 58. By way of example in the practice of the invention, in one embodiment of transducer 30, the array 58 has a total of 16 of the coils 32 arranged in four rows, each of the rows having four of the coils 32, as shown in Fig. 5. Each coil 32 has, typically four or five turns, and has a diameter of approximately two centimeters, with an area of approximately three square centimeters. In a second embodiment of the transducer 30A, there is array 58A of the coils 32A having a total of 24 coils arranged in four rows each having six coils 32A, as shown in Fig. 5A. A cover layer 60 is disposed on top of the substrate 56 and the coils 32. The substrate 56 and the cover layer 60 are formed of a flexible electrically-insulating plastic material which permits flexing of the transducer 30 to conform to the curvature of the subject's head. The coils 32 are formed of a flexible electrically-conductive material such as copper which permits the foregoing flexing of the transducer 30.
In the case of energization of the coils 32 with a sinusoidal current, the generator 40 is operated to output a peak voltage, typically, of four volts relative to ground. This voltage provides a peak current of eight microamperes which is more than enough current to provide a peak magnetic field intensity of 60 picotesla. The output voltage of the generator 40 is adjusted to provide a desired intensity to the resultant alternating magnetic fields. If desired, the resistance of the resistor 42 may be reduced to provide still larger values of current for greater intensity of magnetic fields Upon energization of the coils 32 with electric current, the resultant magnetic fields have lines of force parallel to the axes 62 of the respective coils 32 The locations of the coils 32 provide that the resultant magnetic fields are uniform The driver 38 and the transducer 30 or 30A are capable of providing alternating magnetic fields a frequency range of 0.1 Hz to 10 KHz, and intensity up to 60 microtesla. Typically, in the practice of the invention, the intensity of the alternating magnetic fields is in the range of 7.5 to 75 picotesla, and the frequency is in the range of 5Hz-8Hz Fig 5 shows a sequence of two pulses of magnetic fields wherein the direction and amplitude of the magnetic fields alternate m sinusoidal fashion The sinusoidal form of the alternating magnetic fields is employed in the preferred embodiment of the invention. However, it is understood that some other waveform such as the aforementioned triangular or trapezoidal or square waveform may be used if desired For example, in the case of the trapezoidal waveform, the rise and the fall times of the waveform together may occupy from 20% to 40% of each period of the waveform. Within each pulse, the AC frequency s held constant the preferred embodiment of the invention. However, if desired, the AC frequency may be altered, as by a frequency ramp wherein the frequency increases during the pulse, such that the end frequency is greater than the initial frequency by 10% - 30%. Fig. 5 also shows the duration, A, of the first AC pulse, and the duration, B, of a rest mterval or break between the AC pulses, and the duration, C, of the second AC pulse.
The transmission of signals m the nervous system is such that withm the neuron (nerve cell) transmission is accomplished by propagation of an electrical signal while between neurons signal propagation is accomplished via the mediation of a neurotransmitter A neurotransmitter is a molecule, such as a molecule of serotonin, dopamme, acetylcholine, and histamme, or other neurotransmitter by way of example Durmg the propagation of an electrical signal the neurotransmitter is released from the transmitter neuron ("presynaptic neuron") mto the synaptic cleft from which it diffuses across the synaptic cleft to reach specific receptors in the receiving neuron ( "postsynaptic neuron") . Activation of these receptors at the postsynaptic neuron causes either excitation or inhibition of the postsynaptic neuron. The transmitter neuron and the receiving receptor at the postsynaptic neuron are specific to only one type of neurotransmitter so that a plurality of differ- ent forms of the neuron transmitter/receptor allow for transmis¬ sion of different forms of signals by respective ones of the neurotransmitter.
Neurotransmitters are produced m numerous locations throughout the nervous system. For instance, serotonin is produced in neurons that originate the median raphe of the bramstem and which project to numerous bram areas including the spinal cord, cerebellum, hypothalamus, limbic system, and cortex. In the central nervous system serotonin affects mood, sleep and arousal, satiety, emesis, cardiovascular regulation, temperature control, pain, sedation, anxiety and depression. In the peripheral nervous system, the primary actions of serotonin are on the gastrointestinal tract and cardiovascular system, but it also affects the respiratory tract and genito-urmary system.

Claims

What is claimed is :
Claim 1. A method of retarding the aging process and improving age-related disease conditions in humans which comprises administering to a human in need thereof an effective amount of a composition which increases serotonin transmission to said human followed by the application to the brain of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform.
Claim 2. A method according to Claim 1 wherein the AC pulsed magnetic field is applied to the brain of the human in two applications, separated by an interval of time.
Claim 3. A method according to Claim 1 wherein the composition comprises one or more of the following: an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor into the bram, an effective amount of a stimulant to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors, and is supplemented by an effective amount of a dietary composition rich in the amino-acid tryptophan.
Claim 4. A method according to Claim 2 wherein the duration of the first AC pulsed magnetic field is 10-15 minutes.
Claim 5. A method according to Claim 2 wherein the time delay between the application of the first AC pulsed magnetic field and the second AC pulsed magnetic field is 15-30 minutes.
Claim 6. A method according to Claim 2 wherein the duration of the second AC pulsed magnetic field is 10-15 minutes.
Claim 7. A method according to Claim 1 wherein the AC frequency is 5-8Hz.
Claim 8. A method according to Claim 1 wherein the AC pulsed magnetic field is applied once per week.
Claim 9. A method according to Claim 7 to improve age- related disorders of sleep, mood, behavior, and memory functions wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 10. A method according to Claim 7 for the treatment of hypertension wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 11. A method according to Claim 7 for the treatment of hypercholesterolemia wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 12. A method accordmg to Claim 7 for the treatment of glucose intolerance and overt diabetes mellitus wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 13. A method accordmg to Claim 7 for the treatment of loss or diminished libido wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 14. A method according to Claim 7 for the treatment of bowel constipation wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 15. A method according to Claim 7 for the treatment of psoriasis vulgaris including psoriatic arthropathy wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 16. A method accordmg to Claim 7 for the treatment of osteoarthritis wherein the AC pulsed magnetic field is applied once or twice per week.
Claim 17. A method accordmg to Claim 7 for the treatment of osteoporosis wherein the AC pulsed magnetic field is applied once to twice per week.
Claim 18. A method accordmg to Claim 7 for the treatment of prostate hypertrophy wherem the AC pulsed magnetic field is applied once to twice per week.
Claim 19. A method according to Claim 1 which additionally comprises administering an effective amount of an agent which stimulates growth hormone release prior to application of the first AC pulsed magnetic field.
Claim 20. A method according to Claim 19 wherein the agent is L-arginme or L-ornithme.
Claim 21. A method according to Claim 19 wherein the agent is administered one to two hours prior to the application of the AC pulsed magnetic field.
Claim 22. A method according to Claim 1 wherem the composition is administered four to eight weeks before the application of the first AC pulsed magnetic field.
Claim 23. A method according to Claim 1 wherein the AC pulsed magnetic field is a time varying field with a waveform which is sinusoidal, triangular, trapezoidal, square or a composite thereof.
Claim 24. A method accordmg to Claim 1 wherein the patient's eyes are shielded durmg the application of each AC pulsed magnetic field.
Claim 25. A method according to Claim 1 wherein the magnetic fields are applied to the head using a helmet-like transducer array.
Claim 26. A method accordmg to Claim 25 wherein the helmet-like transducer array comprises an array of coils which are flat or helical.
Claim 27. A method according to Claim 1 wherem the AC pulsed magnetic field is applied at night.
Claim 28. A method according to Claim 23 wherein the application is after 8:00 p.m.
Claim 29. A method according to Claim 1 which includes the serotonin precursor which is L-tryptophan or L-5- hydroxytryptophan.
Claim 30. A method according to Claim 1 which includes the stimulant to facilitate the transport of a serotonin precursor into the brain which is vitamin B3, chromium or a mixture thereof.
Claim 31. A method according to Claim 1 which includes the stimulant to increase plasma tryptophan concentrations which is a salicylate.
Claim 32. A method according to Claim 1 which includes the stimulant of serotonin synthesis which is vitamin B,, vitamin B2, vitamin B3, vitamin B6, biotm, S-adenosylmethionine, folic acid, ascorbic acid, magnesium, coenzyme Q10/ piracetam, or mixtures of two or more thereof .
Claim 33. A method according to Claim 1 which includes the stimulant of serotonin release which is fenfluramine.
Claim 34. A method accordmg to Claim 1 which includes the stimulant of serotonin receptors which is an ergoloid mesylate.
Claim 35. A method according to Claim 1 wherem the dietary composition rich in the ammo-acid tryptophan includes one or more of the following: turkey, milk, bananas, nuts and dry-roasted sunflower seeds.
Claim 36. A method accordmg to Claim 1 wherein the composition additionally comprises an effective amount of an agent which promotes growth hormone release.
Claim 37 A method according to Claim 36 wherein the agent is L-argmme or L-ornithme.
Claim 38. A composition useful for retarding the aging process and improving age-related disease conditions m humans when administered to a human followed by the application to the bram of the human of an effective amount of an AC pulsed magnetic field of proper intensity, frequency and waveform, which composition comprises an effective amount of a composition which increases serotonin transmission to said human.
Claim 39. A composition according to Claim 38 wherein the composition comprises one or more of the following an effective amount of a serotonin precursor, an effective amount of a stimulant to facilitate the transport of a serotonin precursor mto the bra , an effective amount of a stimulant to increase plasma tryptophan concentrations, an effective amount of a stimulant of serotonin synthesis, an effective amount of a stimulant of serotonin release and an effective amount of a stimulant of serotonin receptors.
Claim 40. A composition according to Claim 39 which includes the serotonin precursor which is L-tryptophan or L-5- hydroxytryptophan
Claim 41. A composition according to Claim 39 which includes the stimulant to facilitate the transport of a serotonin precursor into the bram which is vitamin B3, chromium or a mixture thereof.
Claim 42. A composition accordmg to Claim 39 which includes the stimulant to increase plasma tryptophan concentrations which is a salicylate.
Claim 43. A composition accordmg to Claim 39 which includes the stimulant of serotonin synthesis which is vitamin B,, vitamin B2, vitamin B3, vitamin Bή, biotm, S- adenosylmethionine, folic acid, ascorbic acid, magnesium, coenzyme Q10, piracetam or mixtures of two or more thereof.
Claim 44 A composition according to Claim 39 which includes the stimulant of serotonin release which is fenfluramine . Claim 45. A composition accordmg to Claim 39 which includes the stimulant of serotonin receptors which is an ergoloid mesylate.
Claim 46 A composition accordmg to Claim 38 which additionally comprises an effective amount of an agent which promotes growth hormone release
Claim 47 A composition according to Claim 46 wherein the agent is L-argmme or L-ornithme.
PCT/US1996/009440 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions WO1997046244A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002257279A CA2257279A1 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions
IL12740096A IL127400A0 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions
PCT/US1996/009440 WO1997046244A1 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions
AU59898/96A AU5989896A (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002257279A CA2257279A1 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions
PCT/US1996/009440 WO1997046244A1 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions

Publications (1)

Publication Number Publication Date
WO1997046244A1 true WO1997046244A1 (en) 1997-12-11

Family

ID=25680688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009440 WO1997046244A1 (en) 1996-06-06 1996-06-06 Compositions and method which retard the aging process and which improve age-related disease conditions

Country Status (3)

Country Link
CA (1) CA2257279A1 (en)
IL (1) IL127400A0 (en)
WO (1) WO1997046244A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094934A1 (en) * 2002-05-14 2003-11-20 Nipro Corporation Medicine for prevention of and treatment for amyloidosis
US7186209B2 (en) 2003-10-09 2007-03-06 Jacobson Jerry I Cardioelectromagnetic treatment
EP2305346A1 (en) * 2009-10-01 2011-04-06 Albert Hesse Method for treating obesity
US8613695B2 (en) 2008-07-10 2013-12-24 Applied Magnetics, Llc Highly precise and low level signal-generating drivers, systems, and methods of use
US9724534B2 (en) 2008-08-25 2017-08-08 Applied Magnetics, Llc Systems and methods for providing a magnetic resonance treatment to a subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US5157031A (en) * 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157031A (en) * 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHYSICIANS' DESK REFERENCE FOR NON PRESCRIPTION DRUGS, 12th Edition, 1991, pages 584-586. *
PHYSICIANS' DESK REFERENCE, 43rd Edition, 1989, pages 625, 1003-1004, 1701-1702 and 1881. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094934A1 (en) * 2002-05-14 2003-11-20 Nipro Corporation Medicine for prevention of and treatment for amyloidosis
US7186209B2 (en) 2003-10-09 2007-03-06 Jacobson Jerry I Cardioelectromagnetic treatment
US8615293B2 (en) 2003-10-09 2013-12-24 Jacobson Resonance Enterprises, Inc. Cardioelectromagnetic treatment
US8613695B2 (en) 2008-07-10 2013-12-24 Applied Magnetics, Llc Highly precise and low level signal-generating drivers, systems, and methods of use
US9480854B2 (en) 2008-07-10 2016-11-01 Applied Magnetics, Llc Highly precise and low level signal-generating drivers, systems, and methods of use
US9724534B2 (en) 2008-08-25 2017-08-08 Applied Magnetics, Llc Systems and methods for providing a magnetic resonance treatment to a subject
US9821169B2 (en) 2008-08-25 2017-11-21 Applied Magnetics, Llc Systems and methods for providing a magnetic resonance treatment to a subject
EP2305346A1 (en) * 2009-10-01 2011-04-06 Albert Hesse Method for treating obesity
US9005103B2 (en) 2009-10-01 2015-04-14 Albert Hesse Method and device for the treatment of overweight

Also Published As

Publication number Publication date
IL127400A0 (en) 1999-10-28
CA2257279A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
US5691325A (en) Method for ameliorating age-related disease conditions
US5470846A (en) Treatment of neurological and mental disorders
US5691324A (en) Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
Brioche et al. Muscle wasting and aging: experimental models, fatty infiltrations, and prevention
Janowsky et al. Testosterone influences spatial cognition in older men.
Bartsch et al. The pineal gland and cancer: neuroimmunoendocrine mechanisms in malignancy
Tsubokawa et al. Thalamic relay nucleus stimulation for relief of intractable pain. Clinical results and β-endorphin immunoreactivity in the cerebrospinal fluid
EP1224212B1 (en) Tetrapeptide stimulating functional activity of neurones, pharmacological agent based thereon and method of use thereof
JP2003527320A (en) Composition comprising modafinil for the treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
Gersh et al. Applications of transcutaneous electrical nerve stimulation in the management of patients with pain: state-of-the-art update
EA006556B1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
Schoenenberger Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)
Guesdon et al. A tryptic hydrolysate from bovine milk αS1-casein improves sleep in rats subjected to chronic mild stress
Irintchev et al. Glycomimetic improves recovery after femoral injury in a non-human primate
Kubera et al. The effect of chronic treatment with imipramine on the immunoreactivity of animals subjected to a chronic mild stress model of depression
KR101948066B1 (en) L-serine compositions for preventing, improving or treating neurodevelopmental disorders
Xu et al. Mechanism of skeletal muscle atrophy after spinal cord injury: A narrative review
CN115835901A (en) Compositions and methods for treating cancer-related cachexia
WO1997046244A1 (en) Compositions and method which retard the aging process and which improve age-related disease conditions
Leibowitz et al. Neurochemical controls of appetite
JP2004292383A (en) Memory enhancer
WILLIAMS et al. Presidential Address: Metabolism and Mentation
Uzbay et al. Acute and chronic tianeptine treatments attenuate ethanol withdrawal syndrome in rats
Sandyk Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields
MX2014004362A (en) Egg preparation with regenerating, analgesic and/or anti-inflammatory properties.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2257279

Country of ref document: CA

Ref country code: CA

Ref document number: 2257279

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98500521

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)